Change over period: —
NSE · ADVENZYMES
ADVENZYMES
-28.3% from the 52-week high · +13.1% above the low
Advanced Enzyme Technologies Ltd. engages in the research, development, manufacture, and sale of enzyme products. The company is headquartered in Thane, Maharashtra and currently employs 322 full-time employees. The company went IPO on 2016-08-01. The firm is focused on the research and development, manufacturing and marketing of approximately 400 products, which is developed from over 68 indigenous enzymes and probiotics. The company provides solutions to various industries, such as human health care and nutrition, animal nutrition, baking, fruit and vegetable processing, brewing and malting, grain processing, protein modification, dairy processing, specialty applications, textile processing and others. The company offers products and solutions for human nutrition, which include serratiopeptidase, fungal lactase, fungal lipase and papain; animal nutrition, which include DigeGrain X, DigeGrain XL and DigeGrain M; food processing, including dairy and cheese processing and yeast processing, and non-food processing, including textiles processing, leather and bio-fuels. Its oils and fats processing include oil extraction, oil refining fish oil processing, biodiesel and oleochemicals.
The short version. ADVENZYMES reported revenue of ₹215 crore for Sep 2026, up 16.2% from a year earlier. Net profit was ₹48 crore (up 11.6% year on year). Return on equity was 10.3% in Mar 2026. Promoter holding was 43.56% in Sep 2026, up 0.64 points over 8 quarters.
1 · The price
How has the stock traded?
ADVENZYMES trades 28.3% below its 52-week high and 13.1% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹215 cr.
Sep 2026 net profit of ₹48 cr.
1.0 pts lower than a year earlier.
Revenue compounded at 11.3% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 215 | 190 | 203 | 172 | 185 | 186 | 167 | 169 |
| Net profit | 48 | 37 | 43 | 42 | 43 | 40 | 26 | 38 |
| Net margin % | 22.5 | 19.5 | 21.1 | 24.7 | 23.5 | 21.5 | 15.8 | 22.3 |
| EPS (₹) | 4.35 | 3.31 | 3.84 | 3.8 | 3.87 | 3.57 | 2.37 | 3.36 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 746 | 637 | 624 | 541 | 529 | 502 | 444 | 420 |
| Net profit | 169 | 131 | 133 | 106 | 120 | 146 | 129 | 111 |
| Net margin % | 22.6 | 20.6 | 21.4 | 19.5 | 22.6 | 29.1 | 29.1 | 26.5 |
| EPS (₹) | 15.07 | 11.72 | 11.92 | 9.45 | 10.7 | 13.09 | 11.58 | 9.95 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 10.3% in Mar 2026; debt to equity is 0.01.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 10.3 | 9.2 | 10.1 | 8.6 |
| Return on capital % | 13.6 | 12.5 | 13.4 | 10.6 |
| EBITDA margin % | 35.3 | 34.0 | 34.2 | 31.4 |
| Net margin % | 21.6 | 19.6 | 20.2 | 18.7 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 11.3% | 8.9% |
| Profit CAGR | 16.9% | 2.9% |
4 · The owners
Who holds it, and are they adding?
Up 0.64 pts over 8 quarters.
Up 14.07 pts over 8 quarters.
Down 6.29 pts over 8 quarters.
+3 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 42.92 | 43.08 | 43.08 | 43.08 | 43.04 | 43.26 | 43.24 | 43.56 | +0.64 |
| FII | 12.58 | 11.9 | 23.46 | 25.41 | 25.86 | 25.49 | 26.71 | 26.65 | +14.07 |
| DII | 8.18 | 8.19 | 8.45 | 6.41 | 5.51 | 5.41 | 4.78 | 1.89 | -6.29 |
| Public | 36.32 | 36.83 | 25.02 | 25.1 | 25.59 | 25.84 | 25.27 | 27.9 | -8.42 |
Mutual fund holdings · Oct 2026
13 schemes hold this stock
10 the month before.
- UTI - MNC Fund1.12% of NAV
- Motilal Oswal Nifty Microcap 250 Index Fund0.15% of NAV
- Motilal Oswal BSE Healthcare ETF0.08% of NAV
- Bandhan BSE Healthcare Index Fund0.08% of NAV
- JioBlackRock Flexi Cap Fund0.06% of NAV
- Motilal Oswal BSE 1000 Index Fund0.01% of NAV
- Bandhan Nifty Total Market Index Fund0.01% of NAV
- Mirae Asset Nifty Total Market Index Fund0.01% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for ADVENZYMES are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about ADVENZYMES
What is the ADVENZYMES share price?
ADVENZYMES (ADVENZYMES) last closed at ₹296.25, up 5.43% on the day. Its 52-week range is ₹248.35 to ₹392.10.
What is the market cap of ADVENZYMES?
ADVENZYMES has a market capitalisation of about ₹3,123 crore. Its price-to-earnings ratio is 18.4.
How are ADVENZYMES's latest results?
ADVENZYMES reported revenue of ₹215 crore for Sep 2026, up 16.2% from a year earlier. Net profit was ₹48 crore (up 11.6% year on year). Return on equity was 10.3% in Mar 2026. Promoter holding was 43.56% in Sep 2026, up 0.64 points over 8 quarters.
Who owns ADVENZYMES?
As of Sep 2026, shareholding was: Promoter 43.56%, FII 26.65%, DII 1.89%, Public 27.9%.
How many mutual funds hold ADVENZYMES?
13 mutual fund schemes held ADVENZYMES in October 2026. That compares with 10 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 23 Jul 2025 · Final Dividend - Rs. 1.2
- 16 May 2025 · Interim Dividend - Rs. 4
- 18 Jul 2024 · Final Dividend - Rs. 1.1
- 17 May 2024 · Interim Dividend - Rs. 4
- 04 Aug 2023 · Final Dividend - Rs. 1
- 19 May 2023 · Interim Dividend - Rs. 4
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.